October 2010

Greyrock has exited its investment in Alaven Pharmaceutical LLC. Alaven, which provides both prescription and OTC products primary for gastroenterology and women’s health markets, was sold to Meda, AB, a Swedish pharmaceutical company, in a transaction that valued the company at $350 million. Greyrock partnered with DFW Capital Partners in 2006 to provide mezzanine debt and preferred equity to support Alaven’s product acquisition, in-licensing and development strategies.